Moderate to Severe Atopic Dermatitis (DBCOND0031699)

Identifiers

Synonyms

Moderate/Severe Atopic Dermatitis / Moderate-to-Severe Atopic Dermatiti / Moderate-to-severe Atopic Dermatitis

Associated Data

Indicated Drugs and Targets

Drug	Description	Targets
Dupilumab	A monoclonal antibody used to treat moderate to severe atopic dermatitis, asthma, and nasal polyps accompanied by chronic rhinosinusitis in adolescents and adults.	Interleukin-4 receptor subunit alphatarget Interleukin-13target Interleukin-4target
Tralokinumab	A monoclonal antibody directed against interleukin-13 which is used in the treatment of moderate-to-severe atopic dermatitis in patients requiring systemic therapy.	Interleukin-13target

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT01745159	Preventive Treatment of Tacrolimus Ointment in Children With Atopic Dermatitis	Tacrolimus	treatment	4	completed
NCT05899816	A Study Assessing Rocatinlimab on Vaccine Antibody Response in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET - VOYAGER)	Rocatinlimab	basic_science	3	active_not_recruiting
NCT05984784	A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of IMG-007 in Adults With Atopic Dermatitis (AD)	No drug interventions	treatment	1 / 2	terminated
NCT04921345	Pharmacokinetics, Safety and Efficacy of Nemolizumab in Participants With Moderate-to-Severe Atopic Dermatitis	Nemolizumab	treatment	2	recruiting
NCT04805411	Subcutaneously CM310/Placebo in Patients With Moderate-to-Severe Atopic Dermatitis (AD)	Stapokibart	treatment	2	completed
NCT04893707	The Study of CM310 in Patients With Atopic Dermatitis	Stapokibart	treatment	2	unknown_status
NCT05671432	The Study of CM326 in Moderate-to-severe Atopic Dermatitis	No drug interventions	treatment	2	recruiting
NCT03989349	Efficacy & Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis	Nemolizumab	treatment	3	completed
NCT05186922	The Study of CM326 in Patients With Moderate-to-severe Atopic Dermatitis	No drug interventions	treatment	1 / 2	unknown_status
NCT03057860	TREATgermany: German National Clinical Registry for Patients With Moderate-to-severe Atopic Dermatitis	No drug interventions	Not Available	Not Available	recruiting
NCT05017480	A Study to Evaluate the Efficacy and Safety of CBP-201 in Moderate to Severe Atopic Dermatitis in China	Rademikibart	treatment	2	completed
NCT05203380	Neuropsychologic Assessments of Dupilumab-Treated Adolescent Participants With Moderate-to-Severe Atopic Dermatitis	Dupilumab	Not Available	Not Available	completed
NCT03985943	Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis	Nemolizumab	treatment	3	completed
NCT06158490	A Study to Evaluate JYP0061 Tablets in Patients With Moderate-to-severe Atopic Dermatitis	No drug interventions	treatment	2	not_yet_recruiting
NCT05056779	Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis With Inadequate Response to or for Whom Cyclosporine A is Not Medically Advisable	Nemolizumab	treatment	3	withdrawn
NCT03054428	Efficacy and Safety of Dupilumab in Participants ≥12 to <18 Years of Age, With Moderate-to-severe Atopic Dermatitis	Dupilumab	treatment	3	completed
NCT05590585	Dupilumab in Adolescent and Adult Skin of Color Participants: Open-label Moderate-to-severe Eczema Trial	Dupilumab	treatment	4	active_not_recruiting
NCT04444752	A Study to Assess the Efficacy and Safety of CBP-201 in Adult Subjects With Moderate to Severe Atopic Dermatitis	Rademikibart	treatment	2	completed
NCT03989206	Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis	Nemolizumab	treatment	3	active_not_recruiting
NCT04893941	Dose Escalation Trial of CM310 in Patients With Moderate-to-Severe Atopic Dermatitis (AD)	Stapokibart	treatment	1 / 2	completed
NCT06099704	Observational Study of Canadian Patients (6 Years or Older) Receiving Dupixent® for Moderate to Severe Atopic Dermatitis	No drug interventions	Not Available	Not Available	recruiting
NCT05549947	Efficacy and Safety Study of SHR-1819 Injection in Adult Patients With Severe Atopic Dermatitis	No drug interventions	treatment	2	completed
NCT06468956	Efficacy and Safety Study of SHR-1819 Injection in Adult Patients With Severe Atopic Dermatitis	No drug interventions	treatment	3	not_yet_recruiting
NCT06136741	A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis	Rezpegaldesleukin	treatment	2	recruiting
NCT01286220	Dilute Bleach Baths in Pediatric Patients With Atopic Dermatitis	No drug interventions	treatment	Not Available	terminated
NCT03568162	Phase 2b Study to Evaluate the Efficacy and Safety of ISB 830 in Adults With Moderate to Severe Atopic Dermatitis	Telazorlimab	treatment	2	completed
NCT00148746	Standardized Time- and Score-oriented Treatment of Moderate and Severe Atopic Dermatitis	Cyclosporine Pimecrolimus Prednicarbate Prednisolone Tacrolimus	treatment	Not Available	completed
NCT06012812	A Study to Extend Efficacy and Safety of SHR-1819 Injection in Adult Patients With Moderate to Severe Atopic Dermatitis	No drug interventions	treatment	2	enrolling_by_invitation
NCT05197023	A STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF MULTIPLE SUBCUTANEOUS INJECTIONS OF SHR-1819 IN PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS	No drug interventions	treatment	1	unknown_status
NCT06239311	Efficacy and Safety of Methotrexate Versus Placebo in Adults With Atopic Dermatitis.	Methotrexate	treatment	3	recruiting
NCT02426359	Safety and Efficacy Study of Q301 in Moderate to Severe Atopic Dermatitis Patients	No drug interventions	treatment	2	completed
NCT05997927	Efficacy and Safety Clinical Study of VC005 Tablets in Adult Patients With Moderate to Severe Atopic Dermatitis	No drug interventions	treatment	2	completed
NCT05702268	Pharmacodynamic Blood Characteristics of ICP-332 in Patients With Moderate to Severe Atopic Dermatitis	No drug interventions	treatment	2	recruiting